RecruitingPhase 1Phase 2NCT07432633

[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications

A Phase 1/2 Study of [18F]FPyQCP for PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications

Sponsor

Blue Earth Diagnostics

Enrollment

71 participants

Start Date

Mar 18, 2026

Study Type

INTERVENTIONAL

Conditions

Colorectal, Cancer Gastric Cancer Pancreatic Ductal Adenocarcinoma Epithelial Ovarian Cancer Invasive Lobular Breast Carcinoma

Summary

This is a multi-center, open-label, single-arm, Phase 1/2 study designed to evaluate the safety, radiation dosimetry, and preliminary diagnostic performance of \[18F\]FPyQCP in detecting colorectal cancer (CRC), gastric cancer (GC), pancreatic ductal adenocarcinoma (PDAC), invasive lobular breast cancer (ILC), and epithelial ovarian cancer (EOC).

Eligibility

Min Age: 18 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This study uses a new PET scan tracer called [18F]FPyQCP to image a protein called fibroblast activation protein (FAP) — which is found in high amounts in certain tumours — to help doctors better detect and monitor colorectal, gastric, and pancreatic cancers. **You may be eligible if...** - You are between 18 and 80 years old - You have been diagnosed with colorectal cancer, gastric (stomach) cancer, or pancreatic cancer (confirmed by biopsy) - You are in reasonably good health (able to carry out light activity) - You are able and willing to comply with all study procedures **You may NOT be eligible if...** - You have significant kidney or liver problems - You are pregnant or breastfeeding - You have already received treatments that might affect FAP expression - You are unable to provide consent Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.